Answers are grounded in this paper and cite their sources.
Background: Thymic Hypoplasia (HT) in children is a cause of recurrent infections indicative of immunodeficiency. The present study aimed to evaluate the efficacy of Biomodulina T, a thymic polypeptide preparation, in pediatric patients with HT associated or not with cellular immunodeficiency. Methods: A non-controlled, Phase III clinical trial was conducted in children aged 1 to 5 years, including 60 patients, divided into two groups. Group I included 44 patients with HT not associated with cellular immunodeficiency and group II, 16 with cellular immunodeficiency. Patients were treated with Biomodulina T IM during two 4-week cycles with an intermediate 4-week rest period. Patients not reaching a normal thymus size at 16 weeks received a third cycle for 8 weeks. Results: Both groups of patients increased thymus size referred to baseline with no significant differences between them (P>0.05). The mean increase was 67% and 86.5% of patients concluded the treatment with a normal range thymus. Bacterial infections were reduced by 91.5% and viral infections by 80.7%. Consequently, antibiotic consumption was reduced. In patients with cellular immunodeficiency Biomodulina T induced a significant increase in CD4 + T lymphocytes (p<0.05). No significant differences were seen in CD8 + T cells, CD19 + B cells, and CD56 + NK cells. Serum IgA values were also significantly increased. Overall, 82.7% of patients were classified as better, coinciding with normalization of the thymus size and decreasing infections by at least 50%. Conclusions: Treatment of HT in children with Biomodulina T was clinically effective, regardless of the presence or not of cellular immunodeficiency.
No takes yet. Share an insight, caveat, or question.
Peña et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: